{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:40:53Z","timestamp":1795041653560,"version":"4.10.2"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by the interaction between human leukocyte antigen (HLA)-E and the inhibitory receptor, NKG2A. Here, we describe a strategy that overcomes CAR-NK cell inhibition mediated by the HLA-E-NKG2A immune checkpoint. We generate CD33-specific, AML-targeted CAR-NK cells (CAR33) combined with CRISPR\/Cas9-based gene disruption of the NKG2A-encoding\n                    <jats:italic>KLRC1<\/jats:italic>\n                    gene. Using single-cell multi-omics analyses, we identified transcriptional features of activation and maturation in CAR33-\n                    <jats:italic>KLRC1<\/jats:italic>\n                    <jats:sup>ko<\/jats:sup>\n                    -NK cells, which are preserved following exposure to AML cells. Moreover, CAR33-\n                    <jats:italic>KLRC1<\/jats:italic>\n                    <jats:sup>ko<\/jats:sup>\n                    -NK cells demonstrate potent antileukemic killing activity against AML cell lines and primary blasts in vitro and in vivo. We thus conclude that NKG2A-deficient CAR-NK cells have the potential to bypass immune suppression in AML.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-52388-1","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:02:31Z","timestamp":1727672551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2392-6416","authenticated-orcid":false,"given":"Tobias","family":"Bexte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawid","family":"Albinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al Ajami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5844-1587","authenticated-orcid":false,"given":"Philipp","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Buchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-2006","authenticated-orcid":false,"given":"Jamal","family":"Alzubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-2850","authenticated-orcid":false,"given":"Vinzenz","family":"S\u00e4rchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2650-586X","authenticated-orcid":false,"given":"Meike","family":"Vogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-296X","authenticated-orcid":false,"given":"Hadeer Mohamed","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate Anahita","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0865-9582","authenticated-orcid":false,"given":"Raj","family":"Bhayadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0727","authenticated-orcid":false,"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"M\u00f6ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4630","authenticated-orcid":false,"given":"Toni","family":"Cathomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-5872","authenticated-orcid":false,"given":"Michael A.","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Imkeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-1192","authenticated-orcid":false,"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"52388_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","volume":"28","author":"N Albinger","year":"2021","unstructured":"Albinger, N., Hartmann, J. & Ullrich, E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 28, 513\u2013527 (2021).","journal-title":"Gene Ther."},{"key":"52388_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"52388_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"52388_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","volume":"27","author":"N Bouchkouj","year":"2022","unstructured":"Bouchkouj, N. et al. FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist 27, 892\u2013899 (2022).","journal-title":"Oncologist"},{"key":"52388_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"52388_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"52388_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"52388_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"52388_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner, S. et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33, 64\u201374 (2019).","journal-title":"Leukemia"},{"key":"52388_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger, A. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 4, e218 (2014).","journal-title":"Blood Cancer J."},{"key":"52388_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/683065","volume":"2012","author":"A Dutour","year":"2012","unstructured":"Dutour, A. et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv. Hematol. 2012, 683065 (2012).","journal-title":"Adv. Hematol."},{"key":"52388_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e19 (2018).","journal-title":"Cell"},{"key":"52388_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777651","volume":"9","author":"LM Reindl","year":"2020","unstructured":"Reindl, L. M. et al. Immunotherapy with NK cells: recent developments in gene modification open up new avenues. Oncoimmunology 9, 1777651 (2020).","journal-title":"Oncoimmunology"},{"key":"52388_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00262-009-0724-5","volume":"59","author":"MJ Szczepanski","year":"2010","unstructured":"Szczepanski, M. J. et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol. Immunother. 59, 73\u201379 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"52388_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz, J. E. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955\u2013959 (2010).","journal-title":"J. Clin. Oncol."},{"key":"52388_CR16","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee, R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med. 8, 357ra123 (2016).","journal-title":"Sci. Transl. Med."},{"key":"52388_CR17","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051\u20133057 (2005).","journal-title":"Blood"},{"key":"52388_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254\u2013259 (2019).","journal-title":"Nature"},{"key":"52388_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00660-2","volume":"12","author":"N Albinger","year":"2022","unstructured":"Albinger, N. et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 12, 61 (2022).","journal-title":"Blood Cancer J."},{"key":"52388_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","volume":"59","author":"N Albinger","year":"2024","unstructured":"Albinger, N. et al. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transpl. 59, 489\u2013495 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"52388_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature 391, 795\u2013799 (1998).","journal-title":"Nature"},{"key":"52388_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O","volume":"28","author":"E Le Dr\u00e9an","year":"1998","unstructured":"Le Dr\u00e9an, E. et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 28, 264\u2013276 (1998).","journal-title":"Eur. J. Immunol."},{"key":"52388_CR23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743.e13 (2018).","journal-title":"Cell"},{"key":"52388_CR24","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.3389\/fimmu.2018.02743","volume":"9","author":"S Tognarelli","year":"2018","unstructured":"Tognarelli, S. et al. Enhancing the activation and releasing the brakes: a double hit strategy to improve NK cell cytotoxicity against multiple myeloma. Front Immunol. 9, 2743 (2018).","journal-title":"Front Immunol."},{"key":"52388_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2081415","volume":"11","author":"T Bexte","year":"2022","unstructured":"Bexte, T. et al. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. Oncoimmunology 11, 2081415 (2022).","journal-title":"Oncoimmunology"},{"key":"52388_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jleuko\/qiad074","volume":"114","author":"T Bexte","year":"2023","unstructured":"Bexte, T., Reindl, L. M. & Ullrich, E. Nonviral technologies can pave the way for CAR-NK cell therapy. J. Leukoc. Biol. 114, 475\u2013486 (2023).","journal-title":"J. Leukoc. Biol."},{"key":"52388_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.humimm.2004.01.005","volume":"65","author":"TM Holling","year":"2004","unstructured":"Holling, T. M., Schooten, E. & van Den Elsen, P. J. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol. 65, 282\u2013290 (2004).","journal-title":"Hum. Immunol."},{"key":"52388_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fimmu.2017.00535","volume":"8","author":"M Post","year":"2017","unstructured":"Post, M. et al. The transcription factor ZNF683\/HOBIT regulates human NK-cell development. Front. Immunol. 8, 535 (2017).","journal-title":"Front. Immunol."},{"key":"52388_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1083\/jcb.200210158","volume":"160","author":"SS Metkar","year":"2003","unstructured":"Metkar, S. S. et al. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J. Cell Biol. 160, 875 (2003).","journal-title":"J. Cell Biol."},{"key":"52388_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","volume":"40","author":"AK Jayavelu","year":"2022","unstructured":"Jayavelu, A. K. et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40, 301\u2013317.e12 (2022).","journal-title":"Cancer Cell"},{"key":"52388_CR31","unstructured":"013062 - NSG-SGM3 Strain Details. https:\/\/www.jax.org\/strain\/013062#."},{"key":"52388_CR32","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/leu.2010.158","volume":"24","author":"M Wunderlich","year":"2010","unstructured":"Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785\u20131788 (2010).","journal-title":"Leukemia"},{"key":"52388_CR33","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.5001\/omj.2021.108","volume":"36","author":"HM Rasheed","year":"2021","unstructured":"Rasheed, H. M., Donia, H. M., Nadwan, E. A., Mourad, Z. I. & Farahat, N. Identifying leukemia-associated immunophenotypes in acute myeloid leukemia patients using multiparameter flow cytometry. Oman Med. J. 36, e323 (2021).","journal-title":"Oman Med. J."},{"key":"52388_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser, M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138, 2753\u20132767 (2021).","journal-title":"Blood"},{"key":"52388_CR35","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097\u20132100 (2002).","journal-title":"Science"},{"key":"52388_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/cancers13061481","volume":"13","author":"P Wendel","year":"2021","unstructured":"Wendel, P. et al. Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy. Cancers (Basel) 13, 1481 (2021).","journal-title":"Cancers (Basel)"},{"key":"52388_CR37","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","volume":"3","author":"S Cooley","year":"2019","unstructured":"Cooley, S. et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 3, 1970\u20131980 (2019).","journal-title":"Blood Adv."},{"key":"52388_CR38","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41423-020-00574-8","volume":"18","author":"A Crinier","year":"2021","unstructured":"Crinier, A. et al. Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia. Cell Mol. Immunol. 18, 1290\u20131304 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"52388_CR39","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva, O. et al. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity 56, 2816\u20132835.e13 (2023).","journal-title":"Immunity"},{"key":"52388_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fonc.2018.00539","volume":"8","author":"D Schneider","year":"2018","unstructured":"Schneider, D. et al. A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia. Front. Oncol. 8, 539 (2018).","journal-title":"Front. Oncol."},{"key":"52388_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.798087","volume":"12","author":"M Hejazi","year":"2021","unstructured":"Hejazi, M. et al. CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity. Front. Immunol. 12, 798087 (2021).","journal-title":"Front. Immunol."},{"key":"52388_CR42","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","volume":"142","author":"JMT Hunt","year":"2023","unstructured":"Hunt, J. M. T., Samson, C. A., Rand, Adu & Sheppard, H. M. Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum. Genet. 142, 705\u2013720 (2023).","journal-title":"Hum. Genet."},{"key":"52388_CR43","doi-asserted-by":"publisher","first-page":"e0232915","DOI":"10.1371\/journal.pone.0232915","volume":"15","author":"SMAH Rad","year":"2020","unstructured":"Rad, S. M. A. H., Poudel, A., Tan, G. M. Y. & McLellan, A. D. Promoter choice: Who should drive the CAR in T cells? PLoS ONE 15, e0232915 (2020).","journal-title":"PLoS ONE"},{"key":"52388_CR44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","volume":"32","author":"J Klermund","year":"2024","unstructured":"Klermund, J. et al. On- and off-target effects of paired CRISPR-Cas nickase in primary human cells. Mol. Ther. 32, 1298\u20131310 (2024).","journal-title":"Mol. Ther."},{"key":"52388_CR45","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136\u20131147.e5 (2021).","journal-title":"Cell Stem Cell"},{"key":"52388_CR46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/bmt.2008.380","volume":"43","author":"S Nguyen","year":"2009","unstructured":"Nguyen, S. et al. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94\/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transpl. 43, 693\u2013699 (2009).","journal-title":"Bone Marrow Transpl."},{"key":"52388_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2021012411","volume":"141","author":"A Biederst\u00e4dt","year":"2023","unstructured":"Biederst\u00e4dt, A. & Rezvani, K. How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy. Blood 141, 22\u201338 (2023).","journal-title":"Blood"},{"key":"52388_CR48","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"52388_CR49","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624\u2013636 (2021).","journal-title":"Blood"},{"key":"52388_CR50","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.omtm.2023.03.006","volume":"29","author":"D-H Jo","year":"2023","unstructured":"Jo, D.-H. et al. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. Mol. Ther. Methods Clin. Dev. 29, 173\u2013184 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"52388_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46343-3","volume":"15","author":"KB Lupo","year":"2024","unstructured":"Lupo, K. B. et al. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy. Nat. Commun. 15, 1909 (2024).","journal-title":"Nat. Commun."},{"key":"52388_CR52","unstructured":"Research, C. for B. E. and. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. FDA (2023)."},{"key":"52388_CR53","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.ymthe.2024.05.022","volume":"32","author":"T Bexte","year":"2024","unstructured":"Bexte, T. et al. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors. Mol. Ther. 32, 2357\u20132372 (2024).","journal-title":"Mol. Ther."},{"key":"52388_CR54","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood.2023020973","volume":"143","author":"J Kath","year":"2024","unstructured":"Kath, J. et al. Integration of \u03b6-deficient CARs into the CD3\u03b6 gene conveys potent cytotoxicity in T and NK cells. Blood 143, 2599\u20132611 (2024).","journal-title":"Blood"},{"key":"52388_CR55","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3389\/fimmu.2019.03123","volume":"10","author":"S M\u00fcller","year":"2019","unstructured":"M\u00fcller, S. et al. High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia. Front Immunol. 10, 3123 (2019).","journal-title":"Front Immunol."},{"key":"52388_CR56","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","volume":"10","author":"ABL Colamartino","year":"2019","unstructured":"Colamartino, A. B. L. et al. Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector. Front. Immunol. 10, 2873 (2019).","journal-title":"Front. Immunol."},{"key":"52388_CR57","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3389\/fimmu.2019.02001","volume":"10","author":"R Bari","year":"2019","unstructured":"Bari, R. et al. A distinct subset of highly proliferative and lentiviral vector (LV)-transducible NK cells define a readily engineered subset for adoptive cellular therapy. Front. Immunol. 10, 2001 (2019).","journal-title":"Front. Immunol."},{"key":"52388_CR58","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.omtm.2020.12.008","volume":"20","author":"J Alzubi","year":"2021","unstructured":"Alzubi, J. et al. Automated generation of gene-edited CAR T cells at clinical scale. Mol. Ther. Methods Clin. Dev. 20, 379\u2013388 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"52388_CR59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"52388_CR60","doi-asserted-by":"publisher","first-page":"e93031","DOI":"10.1371\/journal.pone.0093031","volume":"9","author":"G Riedel","year":"2014","unstructured":"Riedel, G. et al. An extended \u0394CT-method facilitating normalisation with multiple reference genes suited for quantitative RT-PCR analyses of human hepatocyte-like cells. PLoS ONE 9, e93031 (2014).","journal-title":"PLoS ONE"},{"key":"52388_CR61","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","volume":"33","author":"DJ McCarthy","year":"2017","unstructured":"McCarthy, D. J., Campbell, K. R., Lun, A. T. L. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179\u20131186 (2017).","journal-title":"Bioinformatics"},{"key":"52388_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0888-1","volume":"17","author":"T Ilicic","year":"2016","unstructured":"Ilicic, T. et al. Classification of low quality cells from single-cell RNA-seq data. Genome Biol. 17, 29 (2016).","journal-title":"Genome Biol."},{"key":"52388_CR63","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/biomet\/76.4.643","volume":"76","author":"J AITCHISON","year":"1989","unstructured":"AITCHISON, J. & HO, C. H. The multivariate Poisson-log normal distribution. Biometrika 76, 643\u2013653 (1989).","journal-title":"Biometrika"},{"key":"52388_CR64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"52388_CR65","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"52388_CR66","doi-asserted-by":"crossref","unstructured":"Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 3 (2004).","DOI":"10.2202\/1544-6115.1027"},{"key":"52388_CR67","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1214\/16-AOAS920","volume":"10","author":"B Phipson","year":"2016","unstructured":"Phipson, B., Lee, S., Majewski, I. J., Alexander, W. S. & Smyth, G. K. Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression. Ann. Appl Stat. 10, 946\u2013963 (2016).","journal-title":"Ann. Appl Stat."},{"key":"52388_CR68","doi-asserted-by":"publisher","unstructured":"Wickham, H. Ggplot2 (Springer International Publishing, 2016). https:\/\/doi.org\/10.1007\/978-3-319-24277-4.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"52388_CR69","unstructured":"The igraph software package for complex network research|BibSonomy. https:\/\/www.bibsonomy.org\/bibtex\/bb49a4a77b42229a427fec316e9fe515."},{"key":"52388_CR70","doi-asserted-by":"publisher","first-page":"P10008","DOI":"10.1088\/1742-5468\/2008\/10\/P10008","volume":"2008","author":"VD Blondel","year":"2008","unstructured":"Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech. 2008, P10008 (2008).","journal-title":"J. Stat. Mech."},{"key":"52388_CR71","doi-asserted-by":"publisher","unstructured":"Raivo Kolde. pheatmap: Pretty Heatmaps. 1.0.12 https:\/\/doi.org\/10.32614\/CRAN.package.pheatmap (2010).","DOI":"10.32614\/CRAN.package.pheatmap"},{"key":"52388_CR72","first-page":"2122","volume":"5","author":"ATL Lun","year":"2016","unstructured":"Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).","journal-title":"F1000Res"},{"key":"52388_CR73","unstructured":"van der Maaten, L. & Hinton, G. Visualizing Data using t-SNE. J. Mach. Learn. Res. 9, 2579\u20132605 (2008)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52388-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:04:32Z","timestamp":1727676272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52388-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52388"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52388-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.U. has a sponsored research project with Gilead and BMS and acts as medical advisor of Phialogics and CRIION. T.O. has disclosures to Merck KGaA: Honoraria; Gilead: Research Funding; Merck KGaA: Research Funding; Roche: Honoraria. O.P. has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos, he has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. N.M. is employee of Miltenyi Biotec. T.B., P.W., E.U. have filed patents on data partly published in this manuscript: PCT\/EP2024\/060767: Treatment of leukemia with engineered immune checkpoint inactivated CAR-NK cells and CAR-T cells (U31175WO). No competing interests exists for the remaining authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8439"}}